News
MRNS
0.5500
0.00%
0.00
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals
TipRanks · 02/11/2025 13:58
Weekly Report: what happened at MRNS last week (0203-0207)?
Weekly Report · 02/10/2025 12:04
Weekly Report: what happened at MRNS last week (0127-0131)?
Weekly Report · 02/03/2025 12:11
Weekly Report: what happened at MRNS last week (0120-0124)?
Weekly Report · 01/27/2025 12:15
Weekly Report: what happened at MRNS last week (0113-0117)?
Weekly Report · 01/20/2025 12:03
Weekly Report: what happened at MRNS last week (0106-0110)?
Weekly Report · 01/13/2025 12:04
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
NASDAQ · 01/10/2025 17:00
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
Barchart · 01/06/2025 17:06
Weekly Report: what happened at MRNS last week (1230-0103)?
Weekly Report · 01/06/2025 12:15
Marinus (MRNS) Gets a Hold from Truist Financial
TipRanks · 01/03/2025 12:16
MARINUS PHARMACEUTICALS INC <MRNS.O>: TRUIST SECURITIES REINSTATES TARGET PRICE AT $0.55
Reuters · 01/03/2025 12:07
U.S. RESEARCH ROUNDUP-3M, Citigroup, F5
Reuters · 01/03/2025 06:53
Biotech Alert: Searches spiking for these stocks today
TipRanks · 01/02/2025 16:15
More
Webull provides a variety of real-time MRNS stock news. You can receive the latest news about Marinus Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About MRNS
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.